Elevation of serum adiponectin in mildly decreased glomerular filtration rate

[1]Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003; 148:293–300.DiezJJIglesiasPThe role of the novel adipocyte-derived hormone adiponectin in human diseaseEur J Endocrinol200314829330010.1530/eje.0.148029312611609Search in Google Scholar

[2]Kim HY, Bae EH, Ma SK, Chae DW, Choi KH, Kim Y-S, et al. Association of serum adiponectin level with albuminuria in chronic kidney disease patients. Clin Exp Nephrol. 2016; 20:443–9.KimHYBaeEHMaSKChaeDWChoiKHKimY-Set alAssociation of serum adiponectin level with albuminuria in chronic kidney disease patientsClin Exp Nephrol201620443910.1007/s10157-015-1173-426445954Search in Google Scholar

[3]Sweiss N, Sharma K. Adiponectin effects on the kidney. Best Pract Res Clin Endocrinol Metab. 2014; 28:71–9.SweissNSharmaKAdiponectin effects on the kidneyBest Pract Res Clin Endocrinol Metab20142871910.1016/j.beem.2013.08.002425256724417947Search in Google Scholar

[4]Tungtrongchitr R, Sricharoen P, Pongpaew P, Phonrat B, Arthan D, Vudhivai N, et al. Adiponectin/ACP30, a collagen-like plasma protein in relation to anthropometric measurement in Thai overweight and obese subjects. Int J Food Sci Nutr. 2005; 56:193–201.TungtrongchitrRSricharoenPPongpaewPPhonratBArthanDVudhivaiNet alAdiponectin/ACP30, a collagen-like plasma protein in relation to anthropometric measurement in Thai overweight and obese subjectsInt J Food Sci Nutr20055619320110.1080/0963748050015411316009634Search in Google Scholar

[5]Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Plasma adiponectin levels in overweight and obese Asians. Obesity. 2002; 10:1104–10.YangWSLeeWJFunahashiTTanakaSMatsuzawaYChaoCLet alPlasma adiponectin levels in overweight and obese AsiansObesity20021011041010.1038/oby.2002.15012429873Search in Google Scholar

[6]Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014; 2014:1–14.NigroEScudieroOMonacoMLPalmieriAMazzarellaGCostagliolaCet alNew insight into adiponectin role in obesity and obesity-related diseasesBiomed Res Int2014201411410.1155/2014/658913410942425110685Search in Google Scholar

[7]Aleidi S, Issa A, Bustanji H, Khalil M, Bustanji Y. Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients. Saudi Pharm J. 2015; 23:250–6.AleidiSIssaABustanjiHKhalilMBustanjiYAdiponectin serum levels correlate with insulin resistance in type 2 diabetic patientsSaudi Pharm J201523250610.1016/j.jsps.2014.11.011447581326106273Search in Google Scholar

[8]Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between adiponectin level, insulin sensitivity, and metabolic syndrome in type 1 diabetic patients. Int J Endocrinol. 2013; 2013:1–6.BlaslovKBulumTZibarKDuvnjakLRelationship between adiponectin level, insulin sensitivity, and metabolic syndrome in type 1 diabetic patientsInt J Endocrinol201320131610.1155/2013/535906373022523956744Search in Google Scholar

[9]Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J. 2009; 73:608–14.ShibataROuchiNMuroharaTAdiponectin and cardiovascular diseaseCirc J2009736081410.1253/circj.CJ-09-005719261992Search in Google Scholar

[10]Siasos G, Tousoulis D, Kollia C, Oikonomou E, Siasou Z, Stefanadis C, et al. Adiponectin and cardiovascular disease: mechanisms and new therapeutic approaches. Curr Med Chem. 2012; 19:1193–209.SiasosGTousoulisDKolliaCOikonomouESiasouZStefanadisCet alAdiponectin and cardiovascular disease: mechanisms and new therapeutic approachesCurr Med Chem201219119320910.2174/09298671279932058322257055Search in Google Scholar

[11]Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17:2599–606.MenonVLiLWangXGreeneTBalakrishnanVMaderoMet alAdiponectin and mortality in patients with chronic kidney diseaseJ Am Soc Nephrol200617259960610.1681/ASN.2006040331Search in Google Scholar

[12]Kamimura MA, Canziani MEF, Sanches FR, Velludo CM, Carrero JJ, Bazanelli AP, et al. Variations in adiponectin levels in patients with chronic kidney disease: a prospective study of 12 months. J Bras Nefrol. 2012; 34:259–65.KamimuraMACanzianiMEFSanchesFRVelludoCMCarreroJJBazanelliAPet alVariations in adiponectin levels in patients with chronic kidney disease: a prospective study of 12 monthsJ Bras Nefrol2012342596510.5935/0101-2800.20120007Search in Google Scholar

[13]Saginova E, Galliamov M, Severova M, Surkova O, Fomin V, Ermakov N, et al. The role of leptin, adiponectin and insulin-resistance markers in development of early stages of chronic kidney disease and atherosclerosis of carotid arteries in obese patients. Ter Arkh. 2011; 83:47–53.SaginovaEGalliamovMSeverovaMSurkovaOFominVErmakovNet alThe role of leptin, adiponectin and insulin-resistance markers in development of early stages of chronic kidney disease and atherosclerosis of carotid arteries in obese patientsTer Arkh2011834753Search in Google Scholar

[14]Sedighi O, Abediankenari S. Relationship between plasma adiponectin level with inflammatory and metabolic markers in patients with chronic kidney disease. Nephrourol Mon. 2014; 6:1–4.SedighiOAbediankenariSRelationship between plasma adiponectin level with inflammatory and metabolic markers in patients with chronic kidney diseaseNephrourol Mon201461410.5812/numonthly.11743Search in Google Scholar

[15]Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant. 2006; 22:171–8.ShenYYCharlesworthJAKellyJJLoiKWPeakePWUp-regulation of adiponectin, its isoforms and receptors in end-stage kidney diseaseNephrol Dial Transplant200622171810.1093/ndt/gfl552Search in Google Scholar

[16]James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet. 2010; 375:1296–309.JamesMTHemmelgarnBRTonelliMEarly recognition and prevention of chronic kidney diseaseLancet2010375129630910.1016/S0140-6736(09)62004-3Search in Google Scholar

[17]Decreased G. Definition and classification of CKD. Kidney Int. 2013; 3:19–62.DecreasedGDefinition and classification of CKDKidney Int20133196210.1038/kisup.2012.64408969325018975Search in Google Scholar

[18]Levey AS, Eckardt K-U, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67:2089–100.LeveyASEckardtK-UTsukamotoYLevinACoreshJRossertJet alDefinition and classification of chronic kidney disease: a position statement from kidney disease: Improving Global Outcomes (KDIGO)Kidney Int200567208910010.1111/j.1523-1755.2005.00365.x15882252Search in Google Scholar

[19]Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015; 313:837–46.LeveyASBeckerCInkerLAGlomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic reviewJAMA20153138374610.1001/jama.2015.0602441036325710660Search in Google Scholar

[20]Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63:713–35.InkerLAAstorBCFoxCHIsakovaTLashJPPeraltaCAet alKDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKDAm J Kidney Dis2014637133510.1053/j.ajkd.2014.01.41624647050Search in Google Scholar

[21]Collins AJ, Foley RN, Gilbertson DT, Chen S-C. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 2009; 4:5–11.CollinsAJFoleyRNGilbertsonDTChenS-CThe state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysisClin J Am Soc Nephrol2009451110.2215/CJN.0598080919996006Search in Google Scholar

[22]Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013; 3(Suppl):1–150.Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO2012Clinical Practice Guideline for the evaluation and management of chronic kidney diseaseKidney Int20133Suppl1150Search in Google Scholar

[23]Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:604–12.LeveyASStevensLASchmidCHZhangYLCastroAFFeldmanHIet alA new equation to estimate glomerular filtration rateAnn Intern Med20091506041210.7326/0003-4819-150-9-200905050-00006276356419414839Search in Google Scholar

[24]Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367:20–9.InkerLASchmidCHTighiouartHEckfeldtJHFeldmanHIGreeneTet alEstimating glomerular filtration rate from serum creatinine and cystatin CN Engl J Med201236720910.1056/NEJMoa1114248439802322762315Search in Google Scholar

[25]World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894:1–253.World Health OrganizationObesity: preventing and managing the global epidemic: report of a WHO consultationWorld Health Organ Tech Rep Ser20008941253Search in Google Scholar

[26]Perri A, Vizza D, Lofaro D, Gigliotti P, Leone F, Brunelli E, et al. Adiponectin is expressed and secreted by renal tubular epithelial cells. J Nephrol. 2013; 26:1049–54.PerriAVizzaDLofaroDGigliottiPLeoneFBrunelliEet alAdiponectin is expressed and secreted by renal tubular epithelial cellsJ Nephrol20132610495410.5301/jn.500026923553527Search in Google Scholar

[27]Wolfson N, Gavish D, Matas Z, Boaz M, Shargorodsky M. Relation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor load. Exp Diabetes Res. 2012; 2012:1–5.WolfsonNGavishDMatasZBoazMShargorodskyMRelation of adiponectin to glucose tolerance status, adiposity, and cardiovascular risk factor loadExp Diabetes Res201220121510.1155/2012/250621325510622253614Search in Google Scholar

[28]Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26:3160–7.GenuthSAlbertiKGBennettPBuseJDefronzoRKahnRet alFollow-up report on the diagnosis of diabetes mellitusDiabetes Care2003263160710.2337/diacare.26.11.316014578255Search in Google Scholar

[29]Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines as a link between obesity and chronic kidney disease. Am J Physiol Renal Physiol. 2013; 305:1629–36.BriffaJFMcAinchAJPoronnikPHryciwDHAdipokines as a link between obesity and chronic kidney diseaseAm J Physiol Renal Physiol201330516293610.1152/ajprenal.00263.201324107418Search in Google Scholar

[30]Ix JH, Sharma K. Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J Am Soc Nephrol. 2010; 21:406–12.IxJHSharmaKMechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPKJ Am Soc Nephrol2010214061210.1681/ASN.2009080820447325420150538Search in Google Scholar

[31]Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003; 41:625–33.HallJEThe kidney, hypertension, and obesityHypertension2003416253310.1161/01.HYP.0000052314.95497.7812623970Search in Google Scholar

[32]Eglit T, Lember M, Ringmets I, Rajasalu T. Gender differences in serum high-molecular-weight adiponectin levels in metabolic syndrome. Eur J Endocrinol. 2013; 168:385–91.EglitTLemberMRingmetsIRajasaluTGender differences in serum high-molecular-weight adiponectin levels in metabolic syndromeEur J Endocrinol20131683859110.1530/EJE-12-068823230211Search in Google Scholar

[33]Cnop M, Havel P, Utzschneider K, Carr D, Sinha M, Boyko E, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46:459–69.CnopMHavelPUtzschneiderKCarrDSinhaMBoykoEet alRelationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sexDiabetologia2003464596910.1007/s00125-003-1074-z12687327Search in Google Scholar

[34]Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002; 51:2734–41.NishizawaHShimomuraIKishidaKMaedaNKuriyamaHNagaretaniHet alAndrogens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived proteinDiabetes20025127344110.2337/diabetes.51.9.273412196466Search in Google Scholar

[35]Mamaghani F, Zarghami N, Maleki M, Pourhassan MM, Hosseinpanah F. Variation of adiponectin levels in normal and obese subjects: possible correlation with lipid profiles. Int J Endocrinal Metab. 2009; 3:170–8.MamaghaniFZarghamiNMalekiMPourhassanMMHosseinpanahFVariation of adiponectin levels in normal and obese subjects: possible correlation with lipid profilesInt J Endocrinal Metab200931708Search in Google Scholar

[36]Shoji T, Shinohara K, Hatsuda S, Kimoto E, Fukumoto S, Emoto M, et al. Altered relationship between body fat and plasma adiponectin in end-stage renal disease. Metab Clin Exp. 2005; 54:330–4.ShojiTShinoharaKHatsudaSKimotoEFukumotoSEmotoMet alAltered relationship between body fat and plasma adiponectin in end-stage renal diseaseMetab Clin Exp200554330410.1016/j.metabol.2004.09.01215736110Search in Google Scholar

[37]Obata Y, Yamada Y, Takahi Y, Baden MY, Saisho K, Tamba S, et al. Relationship between serum adiponectin levels and age in healthy subjects and patients with type 2 diabetes. Clin Endocrinol. 2013; 79:204–10.ObataYYamadaYTakahiYBadenMYSaishoKTambaSet alRelationship between serum adiponectin levels and age in healthy subjects and patients with type 2 diabetesClin Endocrinol2013792041010.1111/cen.1204122963459Search in Google Scholar

[38]Christou GA, Tellis K, Elisaf M, Tselepis AD, Kiortsis DN. High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. Hormones. 2012; 11:178.ChristouGATellisKElisafMTselepisADKiortsisDNHigh density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatmentHormones20121117810.14310/horm.2002.134522801564Search in Google Scholar

[39]Tedla F, Brar A, Browne R, Brown C. Hypertension in chronic kidney disease: navigating the evidence. Int J Hypertens. 2011; 2011:1–9.TedlaFBrarABrowneRBrownCHypertension in chronic kidney disease: navigating the evidenceInt J Hypertens201120111910.4061/2011/132405312425421747971Search in Google Scholar

[40]Monhart V. Hypertension and chronic kidney diseases. Cor Vasa. 2013; 55:397–402.MonhartVHypertension and chronic kidney diseasesCor Vasa20135539740210.1016/j.crvasa.2013.07.006Search in Google Scholar